Idorsia Eligible for Royalties on Net Sales in Licensed Territories
Valid market news retained in the public archive without immediate LiveCast distribution.
Story updates
06:04:45 AM UTC
SquawkNews
Idorsia began the pivotal FAB-KLEAR Phase 3 biopsy study of lucerastat in Fabry disease and licensed Japan and selected APAC rights to Nxera, which will pay CHF 7M upfront and co-fund Phase 3. Idorsia keeps royalties and targets a filing as early as 2029.Material DetailsContext by AI AnalystThis ma…